Efficacy and Safety of a Specific Inhibitor of the BCR ABL
We conducted a phase 1 dose escalating trial of STI571 formerly known as CGP 57148B a specific inhibitor of the BCR ABL tyrosine kinase STI571 was administered orally to 83 patients with CML
توليد الكهرباء ويكيبيديا
4 88 388 6 148 5 27 41 72 9 29 637 7 فرنسا 27 22 55 24 439 2 75 8 575 8 البرازيل 13 18 29 59 23 14 13 370 3 20 463 9 كوريا الجنوبية 192 15 81 288 8 151 5 24 446 10 المملكة المتحدة 127